AUTHORS
Haiping Dai, Zhenfang Liu, MD2, Yue Pan3, Depei Wu Sr, MD4, Suning Chen, MD, PhD5
AFFILIATIONS
1 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China
2 The First Affiliated Hospital of Guangxi Medical University, Nanning, China
3 Medical Affairs Department, Beijing, China
4 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China
5 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China
ABSTRACT
Background: Vicrimenib (BN104/S243249), a small-molecule menin inhibitor, demonstrated robust antileukemic efficacy and favorable tolerability in patients with relapsed/refractory (R/R) acute leukemia in a phase 1/2 study (NCT06052813), achieving an overall response rate of 88.9%. However, the safety and efficacy of vicrimenib combined therapy in acute myeloid leukemia (AML) have not yet been characterized.
Methods: This is an open-label, multicenter, phase 1/2 study (NCT06746519) conducted in patients aged ≥18 years with AML, either confirmed KMT2A/NUP98 rearrangement (KMT2Ar/NUP98r), KMT2A-PTD or NPM1 mutation (NPM1m) with intermediate or adverse risk. The trial consists of 3 cohorts: Cohort A enrolled untreated AML patients eligible for intensive chemotherapy. Cohort B enrolled untreated AML patients ineligible for intensive chemotherapy. Cohort C enrolled patients with R/R AML, including those with documented resistance to vicrimenib monotherapy. Patients in cohort A received induction with vicrimenib plus idarubicin 12mg/m2 on days 1-3 and cytarabine 100mg/m2 on days 1-7, followed by up to 4 cycles of high-dose cytarabine plus vicrimenib consolidation. Patients in cohorts B and C received induction with vicrimenib, venetoclax (cycle 1 given as dose escalation from 100 mg on day 1, 200 mg on day 2 and 400mg on day 3 and beyond) and azacitidine (75mg/m2 on days 1-7) (VA). Allogenic stem cell transplantation (allo-HSCT) can be implemented following achievement of complete remission (CR). Across all cohorts, vicrimenib was administrated using a 3+3 dose-escalation design (200mg BID, 400mg BID or 600mg BID), starting on day 4 of cycle 1 and day 1 of subsequent cycles. The primary endpoints were safety and recommended phase 2 dose. Secondary endpoints included composite CR (CRc, defined as CR+CRh+CRi) rate, CR rate, duration of remission and overall survival (OS). Study enrollment was prematurely discontinued as of Sep 1, 2025, following sponsor decision.
Results:
From Nov 2024, 27 patients were screened for eligibility, with 26 ultimately enrolled. The median age of the patients was 40.5(range: 30-58) years, and 12 (46.2%) were male. Among them , 24 (92.3%) had de novo AML, while 2 (7.7%) had secondary AML. Twenty patients (76.9%) were newly diagnosed AML, 2 (7.7%) were relapsed AML and 4 (15.4%) were refractory AML. Four patients (15.4%) had prior exposure to vicrimenib. Risk stratification per ELN criteria revealed intermediate risk in 7 (26.9%) and adverse risk in 19 (73.1%) patients . Seventeen patients had KMT2Ar , 4 had KMT2A-PTD, 4 had NUP98r and 1 had NPM1m. All 26 enrolled patients were evaluable for efficacy and safety. Overall, 22 patients (84.6%) achieved CRc, all were CR. Four patients showed no response. The CRc rates in untreated AML and R/R AML were 90% (18/20) and 66.7% (4/6), respectively, and all were CR. Among treatment-naïve patients, the CR rates were 87.5% (7/8) and 91.7% (11/12) in those receiving vicrimenib plus intensive chemotherapy and plus VA, respectively. The CR rate was 66.7% (4/6) for R/R AML who received vicrimenib plus VA. The 12-month duration of remission rate was 84.7% (95% CI, 59.7-94.8). At the data cutoff date (Jun 1, 2026), only 1 patient had died (due to cerebral hemorrhage unrelated to vicrimenib), and the 12-month OS rate was 91.4% (95% CI, 69.8-97.8). Of the 17 KMT2Ar patients, 15 (88.2%) achieved CR, with 13 (76.5%; 95% CI, 50.1-93.2) attained MRD negative CR. Among the 4 KMT2A-PTD patients, 2 achieved CR, with 1 achieved MRD negative CR. Among 5 patients with other rearrangements, all achieved CR, and 4 (80%) attained MRD negative CR.
Grade ≥3 infections occurred in 12 patients (46.2%), with rates of 62.5% (5/8) in patients receiving vicrimenib plus chemotherapy and 38.9% (7/18) in those receiving vicrimenib plus VA. Sepsis was reported in 1 patient treated with vicrimenib plus chemotherapy, with no cases observed in those receiving vicrimenib plus VA. One patient in the VA group experienced differentiation syndrome. Grade ≥3 QTc prolongation was observed in 2 patients: 1 received vicrimenib plus chemotherapy and 1 was received vicrimenib plus VA.
Conclusion: Vicrimenib-based combination therapies demonstrate high response rates in treatment-naïve AML and notable efficacy in R/R AML with vicrimenib resistance. When combined with VA, vicrimenib exhibits comparable efficacy to intensive chemotherapy combinations, with a favorable safety profile.
DISCLOSURES
Haiping Dai: No relevant conflicts of interest to declare.